Zobrazeno 1 - 10
of 2 429
pro vyhledávání: '"her2-positive breast cancer"'
Autor:
Ran Ran, Shidi Zhao, Yan Zhou, Xinyue Hang, Hui Wang, Yuan Fan, Yusi Zhang, Yifan Qiao, Jin Yang, Danfeng Dong
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-17 (2024)
Abstract Background Different hormone receptor (HR) expression patterns have significant biological and therapeutic implications in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the distinction between
Externí odkaz:
https://doaj.org/article/c62db2b92ea6485b8eea8eb9f1be7b12
Autor:
Mingxia Jiang, Yue Chai, Jiaxuan Liu, Maiyue He, Yipeng Wang, Xue Yang, Zeyu Xing, Mengqi Zhang, Shihan Zhou, Fei Ma, Jiayu Wang, Peng Yuan, Binghe Xu, Qiao Li
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Inetetamab is the first domestically developed innovative anti-HER2 monoclonal antibody in China, proven effective and safe in HER2-positive advanced breast cancer. However, its efficacy and safety in neoadjuvant treatment of HER2
Externí odkaz:
https://doaj.org/article/32387e293c134642a179a5d28b93fb22
Autor:
Debora Gagliato, Tomás Reinert, Cláudio Rocha, Monique Tavares, Sâmio Pimentel, William Fuzita, Márcia Araújo, Danielli Matias, Sabina Aleixo, Bruno França, Érida Magaton, Natália Brito, Ana Carolina Cardoso, Vivienne Castilho
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 437-449 (2024)
Abstract Introduction Biological monoclonal antibodies play a pivotal role in cancer treatment, with biosimilars significantly enhancing their accessibility. In Brazil’s ethnically diverse setting, real-world evidence is crucial for assessing the e
Externí odkaz:
https://doaj.org/article/8914f24dcbdd4abc820ddec9d2ad82a2
Autor:
Elena Giordani, Matteo Allegretti, Alberto Sinibaldi, Francesco Michelotti, Gianluigi Ferretti, Elena Ricciardi, Giovanna Ziccheddu, Fabio Valenti, Simona Di Martino, Cristiana Ercolani, Diana Giannarelli, Grazia Arpino, Stefania Gori, Claudia Omarini, Alberto Zambelli, Emilio Bria, Ida Paris, Simonetta Buglioni, Patrizio Giacomini, Alessandra Fabi
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-11 (2024)
Abstract Background During targeted treatment, HER2-positive breast cancers invariably lose HER2 DNA amplification. In contrast, and interestingly, HER2 proteins may be either lost or gained. To longitudinally and systematically appreciate complex/di
Externí odkaz:
https://doaj.org/article/92bb4cafdd7145c5a75ef4fcaf8a3e78
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-17 (2024)
Abstract Introduction Breast cancer ranks second as the most common malignancy globally, after lung cancer. Among the various subtypes of breast cancer, HER2 positive breast cancer (HER2 BC)poses a particularly challenging prognosis due to its height
Externí odkaz:
https://doaj.org/article/d966eb82613647928dd3133cee8e2b4c
Autor:
Jiaqun Du, Xiaobang Liu, Junpeng Sun, Qian Wu, Yu Hu, Huan Shi, Li Zheng, Ying Liu, Chao Wu, Yu Gao
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-15 (2024)
Abstract In this study, we prepared a bionic nanosystem of trastuzumab-functionalized SK-BR-3 cell membrane hybrid liposome-coated pyrotinib (Ptb-M-Lip-Her) for the treatment of HER2-positive breast cancer. Transmission electron microscopy, dynamic l
Externí odkaz:
https://doaj.org/article/6485fba0eec44caeb898bd1d6133d55f
Autor:
Shuning Liu, Bo Lan, Yuanyi Wang, Tao Yang, Lixi Li, Hewei Ge, Cheng Zeng, Binghe Xu, Haili Qian, Fei Ma
Publikováno v:
EBioMedicine, Vol 109, Iss , Pp 105379- (2024)
Summary: Background: The PHILA study suggests that pyrotinib, trastuzumab, and docetaxel significantly improved progression-free survival (PFS) compared with placebo, trastuzumab, and docetaxel in patients with untreated HER2-positive metastatic brea
Externí odkaz:
https://doaj.org/article/9bb421ef3cf74b95b5cb31e0773cfbb1
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 14, Iss 10, Pp 100977- (2024)
Trastuzumab has improved survival rates in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), but drug resistance leads to treatment failure. Natural killer (NK) cell-mediated antibody-dependent cell cytotoxicity (ADCC) repr
Externí odkaz:
https://doaj.org/article/6b3649ef1f604c7da224a314d7c2ae85
Autor:
Lin Yang, Songhao Chen, Meixue Wang, Shujia Peng, Huadong Zhao, Ping Yang, Guoqiang Bao, Xianli He
Publikováno v:
Heliyon, Vol 10, Iss 19, Pp e38221- (2024)
Despite the approval of several therapeutic agents for HER2-positive breast cancer, drug resistance remains a significant challenge, hindering the patient's prognosis. Thus, our study aimed to establish a risk model to predict the prognosis of patien
Externí odkaz:
https://doaj.org/article/89c69c508099462cab292dc9c0190681
Autor:
Qiao Li, Dan Lv, Xiaoying Sun, Mengyuan Wang, Li Cai, Feng Liu, Chenghui Li, Jiuda Zhao, Jing Sun, Yehui Shi, Fei Ma
Publikováno v:
Cancer Innovation, Vol 3, Iss 5, Pp n/a-n/a (2024)
Abstract Background We explored the efficacy and safety of inetetamab combined with sirolimus and chemotherapy for the treatment of human epidermal factor receptor 2 (HER2)‐positive metastatic breast cancer patients with abnormal activation of the
Externí odkaz:
https://doaj.org/article/6cff81cea58240268e3dd6e588e6951c